Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최호순 | - |
dc.date.accessioned | 2019-11-19T05:33:39Z | - |
dc.date.available | 2019-11-19T05:33:39Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.citation | MEDICINE, v. 96, no. 1, Article no. e5702 | en_US |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.issn | 1536-5964 | - |
dc.identifier.uri | https://insights.ovid.com/article/00005792-201701060-00026 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/112294 | - |
dc.description.abstract | Background: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. Methods: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660mg/m(2) plus Gem 1000mg/m(2) by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion weekly for 3 weeks every 4 weeks). Results: Median overall survival (OS) time, the primary end point, was 10.3 and 7.5 months in the GemCap and Gem arms, respectively (P=0.06). Progression-free survival was 6.2 and 5.3 months in the GemCap and Gem arms, respectively (P=0.08). GemCap significantly improved overall response rate compared with Gem alone (43.7% vs 17.6%; P=0.001). Overall frequency of grade 3 or 4 toxicities was similar in each group. Neutropenia was the most frequent grade 3 or 4 toxicity in both groups. Conclusion: GemCap failed to improve OS at a statistically significant level compared to Gem treatment. This study showed a trend toward improved OS compared to Gem alone. GemCap and Gem both exhibited similar safety profiles. | en_US |
dc.language.iso | en | en_US |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | en_US |
dc.subject | capecitabine | en_US |
dc.subject | gemcitabine | en_US |
dc.subject | overall survival | en_US |
dc.subject | pancreatic cancer | en_US |
dc.subject | progression-free survival | en_US |
dc.title | A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 96 | - |
dc.identifier.doi | 10.1097/MD.0000000000005702 | - |
dc.relation.page | 1-1 | - |
dc.relation.journal | MEDICINE | - |
dc.contributor.googleauthor | Lee, Hee Seung | - |
dc.contributor.googleauthor | Chung, Moon Jae | - |
dc.contributor.googleauthor | Park, Jeong Youp | - |
dc.contributor.googleauthor | Bang, Seungmin | - |
dc.contributor.googleauthor | Park, Seung Woo | - |
dc.contributor.googleauthor | Kim, Ho Gak | - |
dc.contributor.googleauthor | Noh, Myung Hwan | - |
dc.contributor.googleauthor | Lee, Sang Hyub | - |
dc.contributor.googleauthor | Kim, Yong-Tae | - |
dc.contributor.googleauthor | Choi, Ho Soon | - |
dc.relation.code | 2017001922 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | hschoi96 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.